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The c-MET (hereafter referred as MET) receptor tyrosinekinase was originally identified as the cellular homologue
of the TPR-MET oncoprotein.1 MET can be overexpressed in
a number of malignancies, sometimes mutated (germline
mutations/single nucleotide polymorphisms [SNPs] or so-
matic mutations), or sometimes even amplified. MET, located
on chromosome 7 (7q21–q31), encodes for a single precursor
that is posttranscriptionally digested and glycosylated, form-
ing a 50 kDa extracellular -chain and a transmembrane 140
kDa ß-chain, which are then linked by disulfide bonds. The
ligand for MET has been identified as hepatocyte growth
factor (HGF). The MET Sema domain folds into a 7 ß-
propeller structure where blades 2 and 3 bottom face bind to
HGF ß-chain active site region.
Ligation of the MET receptor by HGF leads to receptor
dimerization and activation of its intrinsic tyrosine kinase,
followed by internalization into clathrin-coated vesicles, de-
livery to sorting endosomes, and degradation through the
lysosomal pathway. Phosphorylation of MET at Y1230,
Y1234, and Y1235 in the activation loop of the tyrosine
kinase domain correlates with increased tyrosine kinase ac-
tivity. MET activation can lead to autophosphorylation or
phosphorylation of downstream intermediates and activation
of signaling pathways. Also, Y1003 within the juxtamem-
brane domain recruits c-Cbl (E3-ubiquitin ligase) when phos-
phorylated. A large number of downstream targets have been
defined for MET. As an example, in small cell lung cancer
(SCLC), activation of MET with HGF leads to phosphoryla-
tion/activation of several pathways involving cell prolifera-
tion/survival (ERK1/2 and AKT), cell cycle (RB), and cy-
toskeletal proteins (paxillin and FAK).2
Expression of MET and phospho-MET has been stud-
ied for a number of tumors. In a recent systematic study of a
number of solid tumors, for lung cancer, 28% (1 of 40) of
tumor tissues had no expression (0), whereas 33% (13 of 40)
had 1, 35% (14 of 40) had 2, and 5% (2 of 40) had 3
c-MET expression. Forty percent (16 of 40) of lung cancer
tissues overexpressed MET. In lung cancer, 73% expressed
phospho-MET (1, 14 of 40; 2, 13 of 40; and 3, 2 of 40),
whereas 27% (11 of 40) did not.3
Missense mutations of MET have been reported in a
variety of cancers, with the initial ones identified in the
cytoplasmic activation-loop tyrosine kinase domain. Identifi-
cation of activating mutations of MET in hereditary papillary
renal carcinomas provided the first direct evidence linking
MET directly to human oncogenesis. Germline missense
mutations in the tyrosine kinase (TK) domain are detected in
the majority of hereditary papillary renal cell carcinomas;
somatic mutations have been found in some sporadic papil-
lary renal carcinomas.4 TK domain mutations can occur in
other tumor types such as head and neck cancer5 and glio-
blastomas.6 A number of tumors have been investigated for
MET mutations.3 These mutations could potentially be
germline (including nonsynonymous single nucleotide
polymorphisms, however, referred here as germline) or
somatic. The relative role of germline mutations in non-
hereditary papillary renal cell carcinoma tumors is begin-
ning to be defined. A large number of these solid tumors do
not have mutations in the TK domain, but there are
mutations in the JM and semaphorin Sema domain. JM
domains of receptor tyrosine kinases are thought to be key
regulators of catalytic functions.
We have shown specific JM mutations of MET in
various tumors, such as SCLC, non-SCLC (NSCLC), malig-
nant pleural mesothelioma, melanoma, head and neck cancer,
and pancreatic cancer.7,8 We further showed in a study of 127
adenocarcinoma NSCLC tumors that there were mutations of
MET at R988C, T1010I, and S1058P. These JM domain
mutations of MET led to enhanced tumorigenicity, increased
cell motility, altered cellular architecture, increased MET
phosphorylation, and downstream signal molecule phosphor-
ylation, and stronger response to therapeutic inhibition with
small molecule inhibitors.9 It is possible that these variations
may affect lung cancer risk in carriers.
There are also clusters of mutations within the Sema
domain for certain tumors, alter the binding to HGF, and
seem to be activating mutations. The Sema domain is con-
served among all semaphorins and is also found in the plexins
and MET. In MET, the Sema domain is encoded by exon 2
and binds specifically to HGF. The extracellular ligand-
binding domain in the MET ectodomain was identified as
adopting a seven-blade ß-propeller fold for the Sema domain
of MET, homologous to the ß-propeller fold template seen in
the N-terminal domain of V-integrin.6 MET can also be
amplified in lung cancers. In de novo lung cancers, approx-
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imately 11% of tumors can be amplified for MET.10 MET can
also be amplified in resistance to therapy.
SUMMARY OF PRESENTATIONS
Several MET inhibitors are currently under evaluation
(in vitro cell lines, in vivo mouse models, and clinically).
These inhibitors also include PF2341066, XL880, XL184,
ARQ197, and SGX523. Many of these inhibitors not only
have activity against MET but also against other kinases. As
more inhibitors are brought to clinical fruition, differentiation
will need to be made from specific MET inhibitor to a MET
inhibitor with additional other kinase inhibitory activity.
Importantly, as many tumors may not respond to inhibition of
just one pathway, combinational strategies against MET and
cytotoxic chemotherapies and/or radiation therapy will need
to be implemented. There are not only small molecule inhib-
itors against MET but also antibodies against MET (preclini-
cally and clinically). Most recently, there is MetMAb (anti-
MET antibody) in a phase I clinical trial.
At the Santa Monica Conference, three inhibitors against
MET were presented. They are summarized as below.
XL184
XL 184 is a small molecule inhibitor that can target
MET, vascular endothelial growth factor receptor-2, and RET. A
phase I clinical trial is nearing completion with XL184. The
majority of side effects were diarrhea, nausea, fatigue, liver
function abnormalities, and skin changes. Preclinically,
XL184 can resensitize gefitinib-resistant cells in vitro. In
vivo, there can also be synergism between XL184 and erlo-
tinib. Based on this, a phase I/II clinical trial with XL184 and
erlotinib has been instituted.
PFO2341066
PF02341066 is a small molecule inhibitor that can
target MET and ALK. Also, a phase I clinical trial is ongoing
currently. The maximum tolerated dose was 250 mg twice a
day. Three DLTs were observed: grade 3 increase in ALT
(one patient at 200 mg four times per day) and grade 3 fatigue
(two patients at 300 mg twice a day). The most common
adverse events were nausea, emesis, fatigue, and diarrhea.
Further phase II clinical trials are planned.
MetMAb
MetMAb antibody is an anti-MET monovalent anti-
body that is antagonistic. In an ongoing phase I clinical
trial, MetMAb is given every 3 weeks and cohorts of three
testing 1, 4, 10, 20, and 30 mg/kg. A single DLT of pyrexia
(4 mg/kg) was observed. Common drug-related side ef-
fects (10%) included grades 1 to 2 fatigue (33%) and
grades 1 to 2 nausea and vomiting (14% each). The recom-
mended dose of MetMAb is 15 mg/kg IV every 3 weeks.
Currently, in a phase II study, there is comparison of erlotinib
with MetMAb versus erlotinib with placebo in the second/
third-line NSCLC.
FUTURE DIRECTIONS
MET/HGF pathway is important in a large number of
biologic and biochemical functions for cancer cells. There are
a number of inhibitor strategies currently being used preclini-
cally and clinically. Some MET/HGF inhibitors have already
entered into phase I and/or phase II clinical trials. As we learn
more about tartgeted therapies and combination with stan-
dard or other novel therapies, further clinical trials will be
designed.
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